Yanli Dong

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.

SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.

Journal: American journal of hematology

Published: April 21, 2026

Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.

Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.

Journal: BMC medicine

Published: August 13, 2025

Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.

Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.

Journal: Clinical pharmacokinetics

Published: May 13, 2025

Study on the mechanism of family resilience on loneliness in older adults with stroke.

Study on the mechanism of family resilience on loneliness in older adults with stroke.

Journal: Frontiers in psychology

Published: January 10, 2025

The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects.

The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects.

Journal: Expert opinion on investigational drugs

Published: August 21, 2024

Ursolic acid attenuates oligospermia in busulfan-induced mice by promoting motor proteins.

Ursolic acid attenuates oligospermia in busulfan-induced mice by promoting motor proteins.

Journal: PeerJ

Published: February 20, 2024

Ursonic acid attenuates spermatogenesis in oligozoospermia mice through inhibiting ferroptosis.

Ursonic acid attenuates spermatogenesis in oligozoospermia mice through inhibiting ferroptosis.

Journal: Bioorganic chemistry

Published: December 14, 2023

Automated detection of steps in videos of strabismus surgery using deep learning.

Automated detection of steps in videos of strabismus surgery using deep learning.

Journal: BMC ophthalmology

Published: November 29, 2023

The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.

The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.

Journal: Clinical drug investigation

Published: May 29, 2023

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.

Journal: Frontiers in pharmacology

Published: August 25, 2022

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.

Journal: Frontiers in pharmacology

Published: November 24, 2021

Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

Journal: Clinical and translational science

Published: June 10, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026